Skip to content

Evaluation of efficacy and safety of Platlet-Rich Plasma

Long-term evaluation of efficacy and safety of Platlet-Rich Plasma for human musculoskeletal injury, defect, and delayed healing.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTc030190102
Enrollment
25
Registered
2019-09-20
Start date
2018-12-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disorders of tendon attachment and ligament injury tendinitis, tendinopathy, ligament injury

Interventions

About 30 ml of blood is drawn from the patient.Blood is loaded into the kit. The kit is then centrifuged. The work is done in the clean bench in the Sports wellness outpatient clinic which is authoriz
healing acceleration by self platelet

Sponsors

Funasaki Hiroki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who have disorders of tendon attachment and ligament injury. Patients who have written an informed consent. Patients who have no bacterial infection. Patients who are over 20 years old men and women.

Exclusion criteria

Exclusion criteria: Patients who have bacterial infection including the injection site. Patients who have a risk of affecting their general health in case of bacterial infection by this therapy. Patients who have over 37 degrees of body temperature without using antipyretic or anti-inflammatory. Patients who have open wound. Patients who undergo an oral treatment.

Design outcomes

Primary

MeasureTime frame
Physical findings, Visual Analog Scale and return scale

Secondary

MeasureTime frame
Occurrence of complication

Countries

Japan

Contacts

Public ContactRei Tsuruga

The Jikei University Hospital

tsuruga@gmail.com+81-3-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026